Skip to main content

Socioeconomic Disparities Impact Immunotherapy Use in Urologic Cancers

Medically reviewed by Carmen Pope, BPharm. Last updated on Sep 8, 2024.

By Lori Solomon HealthDay Reporter

FRIDAY, Sept. 6, 2024 -- Immunotherapy (IO) utilization is increasing over time, but significant socioeconomic disparities exist for patients with advanced clear cell renal cell carcinoma (ccRCC) and urothelial carcinoma of the bladder (UC), according to a study published in the November issue of Urologic Oncology: Seminars and Original Investigations.

Levi Holland, M.D., from the University of Texas Southwestern Medical Center in Dallas, and colleagues assessed socioeconomic and demographic factors associated with the receipt of IO for advanced ccRCC and UC. The analysis included patients with stage IV ccRCC (15,926 individuals) or UC (10,380 individuals) identified from the National Cancer Database.

The researchers found that 34.0 percent of patients with ccRCC and 21.5 percent with UC received IO therapy, with IO utilization increasing in each successive year. Treatment at a nonacademic facility, education level, income, and insurance were independently associated with IO utilization for both malignancies. For ccRCC, decreased IO use was seen for Black race (odds ratio, 0.77) and Hispanic race (odds ratio, 0.73). For UC, there were no independent associations noted between race and receipt of IO.

"With the rapidly changing pace of innovation in cancer therapeutics, it is important that all patients have access to novel, potentially lifesaving medications," lead author Solomon Woldu, M.D., also from UT Southwestern, said in a statement. "Our study highlights critical gaps in health care equity when it comes to treatments that have been shown effective in prolonging survival."

Abstract/Full Text (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2025 HealthDay. All rights reserved.

Posted September 2024

Read this next

Testosterone Use Not Tied to Gynecological Cancers in Transmasculine Individuals

FRIDAY, May 16, 2025 -- Short-term testosterone use among transmasculine and gender diverse (TMGD) individuals is not associated with an increased risk for gynecological cancers...

Increases in Incidence Rates of Some Cancers Seen in Early-Onset Age Groups

THURSDAY, May 15, 2025 -- The incidence rates of 14 cancers have increased in early-onset age groups, with increases in older-onset age groups also occurring in most of these...

Aqueous Humor Liquid Biopsy Safe in Pediatric Retinoblastoma

WEDNESDAY, May 14, 2025 -- For pediatric patients with retinoblastoma, aqueous humor liquid biopsy via anterior chamber paracentesis is a safe and well-tolerated procedure...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.